Novo Nordisk has received accelerated approval for Wegovy, the first GLP-1 therapy for metabolic dysfunction-associated steatohepatitis (MASH).
Raluca Ioana Draghici
International
www.shutterstock.com
Always see our news on Google
The FDA has fast-tracked approval of Novo Nordisk's drug Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), affecting 5% of US adults. This is the first GLP-1 class therapy approved for MASH aimed at improving liver function. Preliminary studies have shown promising results, and Novo Nordisk has already applied for approval in Europe and Japan, expecting final trial results in 2029.
Sources
Latest News
19:52
Ukrainian diver, suspected of involvement in the Nord Stream explosions, arrested in Croatia
19:42
The Ministry of National Defense announced a 30% reduction in the CSA Steaua budget, but sports activities are not affected.
19:34
Russia acknowledges that it has started to import fuels due to internal shortages. Details about the volumes and sources of the imports have not been provided.
19:24
Traffic in the Unirii Passage will be temporarily restricted for the next two nights for road tunnel cleaning works.
19:12
Deutsche Telekom acquires the operator Fiberhost and the provider Inea from Poland for approximately 1 billion euros, thus strengthening its position in the telecom market.
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
.webp)
